{"id":"febuprol","rwe":[{"pmid":"3407249","year":"1988","title":"Lipid composition and cholesterol nucleation time in gallbladder bile of patients with cholesterol gallstones under choleretic treatment with Febuprol.","finding":"","journal":"Zeitschrift fur Gastroenterologie","studyType":"Clinical Study"},{"pmid":"3324520","year":"1987","title":"[Lithogenicity and bile acid pattern in choleretic administration (3-n-butoxy-1-phenoxy-propanol: febuprol) in patients with functional right upper quadrant pain].","finding":"","journal":"Zeitschrift fur Gastroenterologie","studyType":"Clinical Study"},{"pmid":"6684447","year":"1983","title":"[Clinical trial of febuprol, a new substance with choleretic activity. Study of efficacy and tolerability].","finding":"","journal":"Arzneimittel-Forschung","studyType":"Clinical Study"},{"pmid":"342924","year":"1978","title":"[Clinical studies on the choleretic agent Febuprol (author's transl)].","finding":"","journal":"MMW, Munchener medizinische Wochenschrift","studyType":"Clinical Study"},{"pmid":"578468","year":"1977","title":"[On the spasmolytic action of 3-butoxy-1-phenoxy-propanol-(2) (febuprol) on the biliary tract (author's transl)].","finding":"","journal":"Arzneimittel-Forschung","studyType":"Clinical Study"}],"tags":[{"label":"febuprol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Cholagogues and Choleretics","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"valbil","offLabel":[],"synonyms":["febuprol","valbil","valbilan"],"timeline":[],"approvals":[],"brandName":"Valbil","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"febuprol","explanation":"Imagine your body's cells have locks on them, and Valbil is a key that fits into those locks. When it binds to the lock, it can either block or enhance the activity of the cell, depending on the type of lock and the key's shape. This interaction can affect various cellular processes, leading to changes in the body's response to different stimuli.","oneSentence":"Valbil is thought to work by interacting with a specific biological target, although the exact mechanism is not well understood.","technicalDetail":"Valbil's mechanism of action is believed to involve the inhibition or activation of a specific protein or receptor, although the precise molecular details are not yet fully elucidated."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1136","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FEBUPROL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:24:48.064543","biosimilars":[],"competitors":[],"genericName":"febuprol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"006658","UNII":"B5RKR9Y63Y","CHEBI":"CHEBI:134924","INN_ID":"3648","RXNORM":"24809","UMLSCUI":"C0060132","ChEMBL_ID":"CHEMBL2104223","KEGG_DRUG":"D07942","PUBCHEM_CID":"71119","MESH_SUPPLEMENTAL_RECORD_UI":"C006281"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":7,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1988 May","pmid":"3407249","title":"Lipid composition and cholesterol nucleation time in gallbladder bile of patients with cholesterol gallstones under choleretic treatment with Febuprol.","journal":"Zeitschrift fur Gastroenterologie"},{"date":"1987 Nov","pmid":"3324520","title":"[Lithogenicity and bile acid pattern in choleretic administration (3-n-butoxy-1-phenoxy-propanol: febuprol) in patients with functional right upper quadrant pain].","journal":"Zeitschrift fur Gastroenterologie"},{"date":"1983","pmid":"6684447","title":"[Clinical trial of febuprol, a new substance with choleretic activity. Study of efficacy and tolerability].","journal":"Arzneimittel-Forschung"},{"date":"1978 Feb 3","pmid":"342924","title":"[Clinical studies on the choleretic agent Febuprol (author's transl)].","journal":"MMW, Munchener medizinische Wochenschrift"},{"date":"1977 Jul","pmid":"578468","title":"[On the spasmolytic action of 3-butoxy-1-phenoxy-propanol-(2) (febuprol) on the biliary tract (author's transl)].","journal":"Arzneimittel-Forschung"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valbil (FEBUPROL) is a small molecule drug of the febuprol class, but specific details about its development, ownership, and commercial status are not available. Its target and mechanism of action are also unknown. As a result, there is limited information available on its approved indications, half-life, bioavailability, and generic manufacturers. Further research is needed to determine its safety profile and potential therapeutic applications. Overall, Valbil's clinical utility and pharmacological properties remain unclear.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}